SK Biopharmaceuticals, Buy Opinion Maintained Despite Target Price Cut… What's the Future of Xcopri?

DS Investment & Securities lowered SK Biopharmaceuticals' target price from KRW 160,000 to KRW 145,000, but maintained a 'Buy' rating. This decision comes despite strong Q1 earnings that significantly exceeded market expectations, reflecting a more conservative outlook on future uncertainties that could impact corporate value.

Get the next 8/10 catalyst

Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 50.1%.

Join Telegram channel or scan with phone →